Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.
CONCLUSION: Severe irAEs occur at a low frequency when anti-PD-1 antibodies are used as monotherapy. Whether anti-PD-1 antibodies combined with systemic chemotherapy increase the incidence of irAEs is not certain.
PMID: 32602470 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Behcet's Disease | Cancer | Cancer & Oncology | Carbohydrates | Chemotherapy | Corticosteroid Therapy | Gastric (Stomach) Cancer | Gastroenterology | Iran Health | Liver | Middle East Health | Oral Cancer | Pancreas | Pancreatic Cancer | Penile Cancer | Rehabilitation | Skin | Toxicology | Urology & Nephrology